Skip to main content

Table 1 Clinical and demographic features of study subjects

From: High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study

 

PEM ± Platinum ± Bev

( n = 301)

PTX + CBDCA + Bev

( n = 80)

P value

Age

66 [39–92]

64 [36–79]

0.025 *

Sex male/female

172/129

54/26

0.094

BMI

21.9 [14.6–33.0]

22.4 [15.2–30.2]

0.137

Smoking history

 Never/past/current

106/122/73

25/33/22

0.754

 Brinkman’s index

400 [0–920]

400 [0–3600]

0.921

 ECOG PS 0/1/2

106/159/36

40/36/4

0.026 *

Pathological diagnosis

 Adenocarcinoma/others

287/14

75/5

0.559

Stage (8th edition)

 IIIB/IIIC/IVA/IVB/Rec/unknown

19/4/110/89/77/2

11/2/26/18/23/0

0.208

Driver mutation

 EGFR ± /unknown

87/200/14

27/49/4

0.679

 ALK ± /unknown

15/227/59

3/56/21

0.410

Therapy line

 1st line/2nd line/others

179/83/39

60/14/6

0.038 *

  1. The data and variabilities are presented as median and range
  2. PEM Pemetrexed, Platinum Cisplatin or Carboplatin, PTX Paclitaxel, CBDCA Carboplatin, Bev Bevacizumab, BMI body mass index, ECOG PS Eastern Cooperative Oncology Group Performance Status, Rec recurrence after definitive treatment (operation or chemoradiation), EGFR epidermal growth factor receptor, ALK anaplastic lymphoma kinase. *: P < 0.05 (Unpaired t-test, Chi-square test)